Please confirm you are human (Sign Up for free to never see this)
← Back to Search
Tuberculosis In Sub-Saharan Africa: Opportunities, Challenges, And Change In The Era Of Antiretroviral Treatment
E. Corbett, B. Marston, G. Churchyard, K. M. Cock
Published 2006 · Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
Rapid scale-up of antiretroviral treatment programmes is happening in Africa, driven by international advocacy and policy directives and supported by unprecedented donor funding and technical assistance. This welcome development offers hope to millions of HIV-infected Africans, among whom tuberculosis is the major cause of serious illness and death. Little in the way of HIV diagnosis or care was previously offered to patients with tuberculosis, by either national tuberculosis or AIDS control programmes, with tuberculosis services focused exclusively on diagnosis and treatment of rising numbers of patients. Tuberculosis control in Africa has yet to adapt to the new climate of antiretroviral availability. Many barriers exist, from drug interactions to historic differences in the way that tuberculosis and HIV are perceived, but failure to successfully integrate HIV and tuberculosis control will threaten the viability of both programmes. Here, we review tuberculosis epidemiology in Africa and policy implications of HIV/AIDS treatment scale-up.
This paper references
Trends in Opportunistic Infections in the Pre–and Post–Highly Active Antiretroviral Therapy Eras Among HIV-Infected Children in the Perinatal AIDS Collaborative Transmission Study, 1986–2004
S. Nesheim (2007)
Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol.
D. Salmon-Céron (2005)
Risk factors for isoniazid (NIH)-induced liver dysfunction.
D. Dickinson (1981)
The mortality and pathology of HIV infection in a West African city
S. Lucas (1993)
Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus.
J. Ungo (1998)
HIV infection and silicosis: the impact of two potent risk factors on mycobacterial disease incidence in South African miners
EL Corbett (2000)
Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults
J. Johnson (2001)
Effectiveness of cotrimoxazole prophylaxis on mortality in adults with tuberculosis in rural South Africa
K. Grimwade (2005)
Antiretroviral Drugs for Tuberculosis Control in the Era of HIV/AIDS
B. Williams (2003)
Provision of antiretroviral therapy to children within the public sector of South Africa.
P. Bock (2008)
Autopsy‐proven causes of death in HIV‐infected patients treated for tuberculosis in Abidjan, Côte d'lvoire
A. Greenberg (1995)
Quantitative bacillary response to treatment in HIV-associated pulmonary tuberculosis.
R. Brindle (1993)
Design of regimens for treating tuberculosis in patients with HIV infection, with particular reference to sub-Saharan Africa.
A. Harries (2001)
Tuberculosis in patients with human immunodeficiency virus infection.
D. Havlir (1999)
[Condom effectiveness in reducing heterosexual HIV transmission].
E. Smith (2002)
Pathology and causes of death in a group of 128 predominantly HIV-positive patients in Botswana, 1997-1998.
N. Ansari (2002)
A review of the diagnosis and treatment of smear-negative pulmonary tuberculosis.
R. Colebunders (2000)
Should the 'bleach microscopy method' be recommended for improved case detection of tuberculosis? Literature review and key person analysis.
K. Angeby (2004)
Isoniazid toxicity in health care workers.
R. Stuart (1999)
Prevention of mother-to-child transmission of human immunodeficiency virus among pregnant women using injecting drugs
C Thorne (2000)
The impact of the HIV epidemic on pulmonary tuberculosis in Karonga district, Malawi: analyses of the evolving relative risk of tuberculosis associated with HIV infection
E Vynnycky (2004)
Tuberculosis case fatality rates in high HIV prevalence populations in sub-Saharan Africa
Y. Mukadi (2001)
Tuberculosis epidemics driven by HIV
C. Currie (2003)
How effectively does HAART restore immune responses to Mycobacterium tuberculosis? Implications for tuberculosis control
S. Lawn (2005)
Patterns of care in two HIV continuity clinics in Uganda, Africa: a time-motion study
M. Were (2008)
What causes smear-negative pulmonary tuberculosis in Malawi, an area of high HIV seroprevalence?
N. Hargreaves (2001)
Tuberculosis control and molecular epidemiology in a South African gold-mining community
P. Godfrey-Faussett (2000)
Adherence to medication regimens among children with human immunodeficiency virus infection
C. Reddington (2000)
Antiretroviral-Associated Toxicity Among HIV-1-Seropositive Pregnant Women in Mozambique Receiving Nevirapine-Based Regimens
L. Jamisse (2007)
Uptake of Workplace HIV Counselling and Testing: A Cluster-Randomised Trial in Zimbabwe
E. Corbett (2006)
Population based screening for active tuberculosis in a community with endemic TB . 33 rd World Conference on Lung Health , 2002 , Montreal , Canada
GJ Churchyard (2005)
An outbreak involving extensive transmission of a virulent strain of Mycobacterium tuberculosis.
S. Valway (1998)
Antiretroviral Pharmacokinetics in the Paediatric Population
J. King (2002)
Tenofovir disoproxil fumarate: a review of its use in the management of HIV infection.
K. Lyseng-Williamson (2005)
Human resources for health : overcoming the crisis
Joint Learning Initiative (2004)
Tuberculosis Chemotherapy Centre . The prevention and treatment of isoniazid toxicity in the therapy of pulmonary tuberculosis
Effect of Rifampin on Steady-State Pharmacokinetics of Atazanavir with Ritonavir in Healthy Volunteers
D. Burger (2006)
Tuberculosis deaths in countries with high HIV prevalence: what is their use as an indicator in tuberculosis programme monitoring and epidemiological surveillance?
D. Maher (2005)
Sero‐Discordant Couples in Five African Countries: Implications for Prevention Strategies
D. Walque (2007)
Reduced risk of tuberculosis among Brazilian patients with advanced human immunodeficiency virus infection treated with highly active antiretroviral therapy.
G. Santoro-Lopes (2002)
Scaling up access to antiretroviral treatment in southern Africa: who will do the job?
K. Kober (2004)
A decline in community viral load in Cape Town and Johannesburg, South Africa
S Carmona (2004)
Effect of Concomitantly Administered Rifampin on the Pharmacokinetics and Safety of Atazanavir Administered Twice Daily
E. Acosta (2007)
Latent Mycobacterium tuberculosis–persistence, patience, and winning by waiting
Y. Manabe (2000)
When to initiate highly active antiretroviral therapy: a cohort approach.
Linda Ahdieh-Grant (2003)
Human resources for health: overcoming the crisis
L. Chen (2004)
A national study of clinical and laboratory factors affecting the survival of patients with multiple drug resistant tuberculosis in the UK
F. Drobniewski (2002)
Isoniazid preventive therapy, hepatitis C virus infection, and hepatotoxicity among injection drug users infected with Mycobacterium tuberculosis.
P. Sadaphal (2001)
Chest radiographic findings in patients with tuberculosis with recent or remote infection.
B. Jones (1997)
A comparison of direct microscopy, the concentration method and the Mycobacteria Growth Indicator Tube for the examination of sputum for acid-fast bacilli.
L. Apers (2003)
A model of integrated primary care for HIV-positive patients with underlying substance use and mental illness
N. Zaller (2007)
Utility of tuberculosis directly observed therapy programs as sites for access to and provision of antiretroviral therapy in resource-limited countries.
G. Friedland (2004)
Acceptance and safety of directly observed versus self-administered isoniazid preventive therapy in aboriginal peoples in British Columbia.
G. Heal (1998)
How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults?
G. Comstock (1999)
From the Food and Drug Administration.
J. Samet (2002)
Validation of self-report and hospital pill count using unannounced home pill count as methods for determination of adherence to antiretroviral therapy.
O. Minzi (2008)
Impact of human immunodeficiency virus type-1 infection on the initial bacteriologic and radiographic manifestations of pulmonary tuberculosis in Uganda
J. L. Johnson (1998)
HIV-related tuberculosis: how well are we doing with current control efforts?
D. Maher (2005)
Serum transaminase elevations and other hepatic abnormalities in patients receiving isoniazid.
L. Scharer (1969)
Periconceptional exposure to efavirenz and neural tube defects.
M. De Santis (2002)
Efavirenz in Human Breast Milk, Mothers', and Newborns' Plasma
S. Schneider (2008)
Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis
H. Thein (2008)
Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Côte d'Ivoire: a randomised controlled trial
S. Wiktor (1999)
Missed opportunities for prevention of tuberculosis among persons with HIV infection--selected locations, United States, 1996-1997.
Cohort study of HIV-positive and HIV-negative tuberculosis, Nairobi, Kenya: comparison of bacteriological results.
W. Githui (1992)
Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru
P. Suarez (2002)
Acute respiratory infections (A. R. I.) in an outlying health formation: Epidemiology and cares
A. Andrianarisoa (1994)
Treatment of Latent Tuberculosis Infection in Contacts of New Tuberculosis Cases in the United States
M. Reichler (2002)
Nevirapine‐associated toxicity in HIV‐infected Thai men and women, including pregnant women
N. Phanuphak (2007)
Reasons for loss to follow-up among mothers registered in a prevention-of-mother-to-child transmission program in rural Malawi.
L. D. Bwirire (2008)
Pyridoxine supplementation during isoniazid therapy.
D. Snider (1980)
Comparison of two versus three smears in identifying culture-positive tuberculosis patients in a rural African setting with high HIV prevalence.
A. Crampin (2001)
GUIDELINES FOR THE PREVENTION OF TUBERCULOSIS IN HEALTH CARE FACILITIES IN RESOURCE-LIMITED SETTINGS
R. Granich (1999)
Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study.
R. Weber (2006)
Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine
J. Macías (2004)
Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis.
E. Ribera (2001)
Assessing the impact of HIV on the annual risk of TB infection using a mathematical model
C. Currie (2005)
Rifampicin and isoniazid prophylactic chemotherapy for tuberculosis
L. Ormerod (1998)
'Smear-negative' pulmonary tuberculosis in a DOTS programme: poor outcomes in an area of high HIV seroprevalence.
N. Hargreaves (2001)
Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial
The Tuberculosis Trials Consortium (2002)
The Evolving Epidemiology of HIV Infection and Tuberculosis in Northern Thailand
P. Siriarayapon (2002)
The prognosis of a positive tuberculin reaction in childhood and adolescence.
G. Comstock (1974)
The impact of human immunodeficiency virus on presentation and diagnosis of tuberculosis in a cohort study in Zambia.
A. Elliott (1993)
Isoniazid toxicity. A prospective study in secondary chemoprophylaxis.
C. B. Byrd (1972)
Decline in HIV infectivity following the introduction of highly active antiretroviral therapy
T. Porco (2004)
Clinical diagnosis of smear-negative pulmonary tuberculosis in low-income countries: the current evidence.
K. Siddiqi (2003)
Mycobacterial disease in South African gold miners in the era of HIV infection.
G. Churchyard (1999)
Anti-tuberculosis drug resistance in the world: The WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Geneva: World Health Organization, 1997. 228pp. Price Sw. fr 25/US$22.50 (in developing countries Sw. fir 17.50). (Reference WHO/TB/97.229)
D. Wilkinson (1998)
The effect of isoniazid on transaminase levels.
W. Bailey (1974)
A Pilot Study of Food Supplementation to Improve Adherence to Antiretroviral Therapy Among Food-Insecure Adults in Lusaka, Zambia
R. Cantrell (2008)
Accuracy of routine diagnosis of pulmonary tuberculosis in an area of high HIV prevalence.
L. Apers (2004)
Global trends in resistance to antituberculosis drugs. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance.
M. Espinal (2001)
Antiretroviral medication adherence among the REACH HIV-infected adolescent cohort in the USA
D. Murphy (2001)
Implementing antiretroviral therapy in rural communities: the Lusikisiki model of decentralized HIV/AIDS care.
M. Bedelu (2007)
Screening pulmonary tuberculosis suspects in Malawi: testing different strategies.
A. Harries (1997)
Tenofovir Disoproxil Fumarate and an Optimized Background Regimen of Antiretroviral Agents as Salvage Therapy for Pediatric HIV Infection
R. Hazra (2005)
Should tuberculosis (TB) clinics provide (or refer for) antiretroviral therapy
S Royce (2008)
Tuberculosis and the HIV epidemic: increasing annual risk of infection in Kenya
Ja Odhiambo (1986)
Integrating tuberculosis and HIV care in the primary care setting in South Africa
D. Coetzee (2004)
Correlates of Hepatitis C Virus Infections among Injection Drug Users
D. Thomas (1995)
Nosocomial transmission of multidrug-resistant tuberculosis among HIV-infected persons--Florida and New York, 1988-1991.
The Adult/Adolescent Spectrum of HIV Disease Group. HIV associated TB in the era of HAART
JL Jones (2000)
Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection
J. Pape (1993)
HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers
P. Sonnenberg (2001)
Controlling multidrug-resistant tuberculosis and access to expensive drugs: a rational framework.
A. Pablos-Mendez (2002)
CD4+ T-Cell Count Monitoring Does Not Accurately Identify HIV-Infected Adults With Virologic Failure Receiving Antiretroviral Therapy
D. Moore (2008)
A Comprehensive Hepatic Safety Analysis of Nevirapine in Different Populations of HIV Infected Patients*
J. O. Stern (2003)
Community viral load counts and new HIV-positive patients
K Manavi (2006)
Long-Term CD4+ T-Cell Response to Highly Active Antiretroviral Therapy According to Baseline CD4+ T-Cell Count
F. García (2004)
A Pilot Study of Once-Daily Antiretroviral Therapy Integrated With Tuberculosis Directly Observed Therapy in a Resource-Limited Setting
Christopher D. Jack (2004)
Tuberculosis epidemics driven by HIV: is prevention better than cure?
C. Currie (2003)
Validating clinical and immunological definitions of antiretroviral treatment failure in Malawi
M Hosseinipour (2007)
The impact of HIV infection on recurrence of tuberculosis in South African gold miners.
K. F. Mallory (2000)
Late postnatal transmission of HIV-1 in breast-fed children: an individual patient data meta-analysis.
A. Coutsoudis (2004)
Priorities for the treatment of latent tuberculosis infection in the United States.
C. Horsburgh (2004)
CD4 Cell Counts of 800 Cells/mm3 or Greater After 7 Years of Highly Active Antiretroviral Therapy Are Feasible in Most Patients Starting With 350 Cells/mm3 or Greater
L. Gras (2007)
Clinical management of tuberculosis in the context of HIV infection.
B. D. de Jong (2004)
Patient support and education for promoting adherence to highly active antiretroviral therapy for HIV/AIDS.
M. Haddad (2000)
The impact of malnutrition on survival and the CD4 count response in HIV‐infected patients starting antiretroviral therapy
N. Paton (2006)
Strategies for reducing the burden of TB infection and disease in high HIV prevalence populations: modelling the impact of active case finding, antiretrovirals and preventive therapy
EL Corbett (2002)
A multi-institutional outbreak of highly drug-resistant tuberculosis: epidemiology and clinical outcomes.
T. Frieden (1996)
Interventions to reduce tuberculosis mortality and transmission in low- and middle-income countries.
M. Borgdorff (2002)
Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis.
E. Nuermberger (2004)
HIV coinfection shortens the survival of patients with hepatitis C virus–related decompensated cirrhosis
Carla W Brady (2005)
Treatment of HIV-related tuberculosis in the era of effective antiretroviral therapy.
W. Burman (2001)
Impact of HIV infection on rates of recurrence after treatment for tuberculosis in South African gold miners
KM Mallory (2000)
Risk factors for active tuberculosis after antiretroviral treatment initiation in Abidjan.
C. Seyler (2005)
Recurrent tuberculosis in HIV-infected patients in Rio de Janeiro, Brazil
J. Golub (2008)
WHO public health approach to ART against HIV in resource-limited settings
C Gilks (2006)
Incidence and determinants of mortality and morbidity following early antiretroviral therapy initiation in HIV-infected adults in West Africa
R. Moh (2007)
The host immune response to tuberculosis.
N. Schluger (1998)
Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months.
D. Menzies (2004)
Risk factors for active tuberculosis following antiretroviral treatment initiation in Abidjan
C Seyler (2005)
48 week virological response to a triple nucleoside/nucleotide analogue regimen in adults with HIV infection in Africa within the DART trial.
P. Kaleebu (2005)
Impact of human immunodeficiency virus type-1 infection on the initial bacteriologic and radiographic manifestations of pulmonary tuberculosis in Uganda. Makerere University-Case Western Reserve University Research Collaboration.
J. Johnson (1998)
Current CD4 cell count and the short-term risk of AIDS and death before the availability of effective antiretroviral therapy in HIV-infected children and adults.
D. Dunn (2008)
Toxic effects of isoniazid in tuberculosis chemoprophylaxis. Role of biochemical monitoring in 1,000 patients.
R. B. Byrd (1979)
Can we get more HIV-positive tuberculosis patients on antiretroviral treatment in a rural district of Malawi?
R. Zachariah (2005)
HIV-associated tuberculosis in the era of highly active antiretroviral therapy. The Adult/Adolescent Spectrum of HIV Disease Group.
J. Jones (2000)
HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load.
A. Phillips (2001)
Survival Benefit of Initiating Antiretroviral Therapy in HIV-Infected Persons in Different CD4+ Cell Strata
F. Palella (2003)
Isoniazid preventive therapy.
S. Salpeter (1996)
Low levels of drug resistance amidst rapidly increasing tuberculosis and human immunodeficiency virus co-epidemics in Botswana.
T. Kenyon (1999)
Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study
A. Mocroft (2007)
When to start highly active antiretroviral therapy in chronically HIV-infected patients: evidence from the ICONA study
A. C. Lepri (2001)
CD4R count and risk of non-AIDS diseases following initial treatment for HIV infection
JV Baker (2008)
The sound of one hand clapping: tuberculosis and antiretroviral therapy in Africa.
K. D. De Cock (2005)
Decreased bone mineral density with off-label use of tenofovir in HIV-infected children and adolescents
J Purdy (2008)
Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults
M. Quigley (2001)
Transmission of Mycobacterium tuberculosis associated with failed completion of treatment for latent tuberculosis infection--Chickasaw County, Mississippi, June 1999-March 2002.
T. Chamblee (2003)
Trial of Shortened Zidovudine Regimens to Prevent Mother-to-Child Transmission of Human Immunodeficiency Virus Type 1
M. Lallemant (2001)
Evaluation of a home-based voluntary counselling and testing intervention in rural Uganda.
B. Wolff (2005)
Low access to a highly effective therapy: a challenge for international tuberculosis control.
C. Dye (2002)
Tuberculosis bacteriology--priorities and indications in high prevalence countries: position of the technical staff of the Tuberculosis Division of the International Union Against Tuberculosis and Lung Disease.
A. Deun (2005)
HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS)
C. Thio (2002)
Interim policy on collaborative TB / HIV activities.
H. Getahun (2004)
Human immunodeficiency virus and the prevalence of undiagnosed tuberculosis in African gold miners.
E. Corbett (2004)
Impact of highly active antiretroviral treatment on HIV seroincidence among men who have sex with men: San Francisco.
M. Katz (2002)
Adherence to Antiretroviral Therapy Assessed by Unannounced Pill Counts Conducted by Telephone
S. Kalichman (2007)
Response to treatment, mortality, and CD4 lymphocyte counts in HIV-infected persons with tuberculosis in Abidjan, Côte d'Ivoire
A. Ackah (1995)
How well have 2006 WHO guidelines on cotrimoxazole prophylaxis (CTXp) been incorporated into national guidelines in resource-limited settings (RLS)
P Gavrilidis G Easterbrook (2006)
Chemoprophylaxis for tuberculosis and survival of HIV-infected patients in Brazil
A. M. de Pinho (2001)
Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals.
S. Lawn (2005)
Global tuberculosis control: surveillance planning financing. WHO report 2008.
C. Dye (2003)
The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: evidence from the MANIF2000 cohort study.
P. Roux (2008)
Will DOTS do it? A reappraisal of tuberculosis control in countries with high rates of HIV infection.
De Cock Km (1999)
Tuberculosis control in the era of the HIV epidemic: risk of tuberculosis infection in Tanzania, 1983-1998.
Hepatotoxicity associated with nevirapine or efavirenz‐containing antiretroviral therapy: Role of hepatitis C and B infections
M. Sulkowski (2002)
Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis.
E. Arrivé (2007)
Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study
M. Badri (2002)
HIV Risk Factors Reported by Two Samples of Male Bathhouse Attendees in Los Angeles, California, 2001–2002
T. Bingham (2008)
A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand
G. Matthews. (2008)
Anonymous HIV testing using home collection and telemedicine counseling. A multicenter evaluation.
A. Frank (1997)
Effect of preventive treatment for tuberculosis in adults infected with HIV: systematic review of randomised placebo controlled trials
D. Wilkinson (1998)
Asymptomatic hepatitis in persons who received alternative preventive therapy with pyrazinamide and ofloxacin.
R. Ridzon (1997)
The growing burden of tuberculosis: global trends and interactions with the HIV epidemic.
E. Corbett (2003)
Health sector reform and tuberculosis control: the case of Zambia.
M. Bosman (2000)
Isoniazid hepatitis in adolescents.
I. Litt (1976)
Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy.
J. Kaplan (2000)
Sensitivity and specificity of using CD4+ measurement and clinical evaluation to determine antiretroviral treatment failure in Thailand.
R. Chaiwarith (2007)
A comprehensive comparison of Ziehl-Neelsen and fluorescence microscopy for the diagnosis of tuberculosis in a resource-poor urban setting.
L. Kivihya-Ndugga (2003)
A Successful Workplace Program for Voluntary Counseling and Testing and Treatment of HIV/AIDS at Heineken, Rwanda
F. Feeley (2007)
Long-term outcome in patients registered with tuberculosis in Zomba, Malawi: mortality at 7 years according to initial HIV status and type of TB.
C. Kang'ombe (2004)
Isoniazid preventive therapy in human immunodeficiency virus-infected persons. Long-term effect on development of tuberculosis and survival.
S. Moreno (1997)
Directly administered antiretroviral therapy in methadone clinics is associated with improved HIV treatment outcomes, compared with outcomes among concurrent comparison groups.
G. Lucas (2006)
Pharmacy Refill Adherence Compared with CD4 Count Changes for Monitoring HIV-Infected Adults on Antiretroviral Therapy
G. Bisson (2008)
Rifampin preventive therapy for tuberculosis in Boston's homeless.
A. Polesky (1996)
Hepatotoxicity of rifampin and pyrazinamide in the treatment of latent tuberculosis infection in HIV-infected persons: is it different than in HIV-uninfected persons?
F. Gordin (2004)
Preventive therapy against tuberculosis in people living with HIV.
Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial
A. Jindani (2004)
Establishing CD4 thresholds for highly active antiretroviral therapy initiation in a cohort of HIV-infected adult Chinese in Hong Kong.
K. Wong (2007)
Impact of the HIV epidemic on trends in tuberculosis in Abidjan, Côte d'Ivoire.
S. B. Richards (1995)
Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda
J. Mermin (2004)
An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. An analysis using restriction-fragment-length polymorphisms.
C. Daley (1992)
Human resources for control of tuberculosis and HIV-associated tuberculosis.
A. Harries (2005)
Response to antiretroviral therapy after a single, peripartum dose of nevirapine.
S. Lockman (2007)
Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy
G. Dean (2002)
Voluntary counselling, HIV testing and adjunctive cotrimoxazole are associated with improved TB treatment outcomes under routine conditions in Thyolo District, Malawi.
R. Chimzizi (2004)
Chronic cough in primary health care attendees, Harare, Zimbabwe: diagnosis and impact of HIV infection.
S. Munyati (2005)
Tuberculosis morbidity in a controlled trial of the prophylactic use of isoniazid among household contacts.
S. Ferebee (1962)
High rates of clinical and subclinical tuberculosis among HIV-infected ambulatory subjects in Tanzania.
L. Mtei (2005)
How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners.
P. Sonnenberg (2005)
Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients
Y. Benhamou (1999)
A comprehensive study of the efficiency of the routine pulmonary tuberculosis diagnostic process in Nairobi.
M. van Cleeff (2003)
New Measurable Indicator for Tuberculosis Case Detection
M. Borgdorff (2004)
Trends in tuberculosis and the influence of HIV infection in northern Malawi, 1988-2001.
M. Borgdorff (2004)
Prevalence and predictive value of intermittent viremia with combination hiv therapy.
D. Havlir (2001)
Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review
Bradley M. Mathers (2008)
Conservation of first-line antiretroviral treatment regimen where therapeutic options are limited.
C. Orrell (2007)
Barriers to HAART adherence among human immunodeficiency virus-infected adolescents.
D. Murphy (2003)
Chronic diarrhoea among HIV-infected adult patients in Nairobi, Kenya
C. Mwachari (1998)
Body Mass Index at Time of HIV Diagnosis: A Strong and Independent Predictor of Survival
M. V. D. van der Sande (2004)
HIV infection and silicosis: the impact of two potent risk factors on the incidence of mycobacterial disease in South African miners
E. Corbett (2000)
Isoniazid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomized controlled trials.
H. Bucher (1999)
Decreased HIV transmission after a policy of providing free access to highly active antiretroviral therapy in Taiwan.
C. Fang (2004)
Adherence to Antiretroviral Therapy Among HIV-Infected Drug Users: A Meta-Analysis
M. Malta (2008)
Patient, Caregiver and Regimen Characteristics Associated With Adherence to Highly Active Antiretroviral Therapy Among HIV-Infected Children and Adolescents
S. Martin (2007)
Improved plausibility bounds about the 2005 HIV and AIDS estimates
M. Morgan (2006)
HIV associated TB in the era of HAART
JL Jones (2000)
Trends in tuberculosis and the influence of HIV infection in northern Malawi, 1988–2001
J. Glynn (2004)
The M184V Mutation in the Reverse Transcriptase of Human Immunodeficiency Virus Type 1 Impairs Rescue of Chain-Terminated DNA Synthesis
M. Götte (2000)
Nosocomial spread of human immunodeficiency virus-related multidrug-resistant tuberculosis in Buenos Aires.
V. Ritacco (1997)
Changing Clinical Presentation and Survival in HIV‐Associated Tuberculosis After Highly Active Antiretroviral Therapy
E. Girardi (2001)
Are smear-positive pulmonary tuberculosis patients a 'sentinel' population for the HIV epidemic in Cameroon?
J. Noeske (2004)
Mortality for liver disease in patients with HIV infection: a cohort study.
M. Puoti (2000)
A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration.
C. Whalen (1997)
Prevalence of HIV and other sexually transmitted infections among female sex workers in Kisumu, western Kenya
HM Vandenhoudt (1997)
Will DOTS do it? A reappraisal of tuberculosis control in countries with high rates of HIV infection.
K. D. De Cock (1999)
Random - ised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV - 1 infection
NA Halsey (1998)
Resources Required for Global Tuberculosis Control
K. Floyd (2002)
Toxic hepatitis with isoniazid and rifampin. A meta-analysis.
M. Steele (1991)
Antiretroviral therapy for TB control in the era of HIV/AIDS
BG Williams (2003)
Fair process in patient selection for antiretroviral treatment in WHO's goal of 3 by 5
N. Daniels (2005)
Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic.
C. Nolan (1999)
Initiating highly active antiretroviral therapy in sub-Saharan Africa: an assessment of the revised World Health Organization scaling-up guidelines
M. Badri (2004)
The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil
J. Golub (2007)
Implementing joint TB and HIV interventions in a rural district of Malawi: is there a role for an international non-governmental organisation?
R. Zachariah (2004)
Twice weekly tuberculosis preventive therapy in HIV infection in Zambia
A. Mwinga (1998)
Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study.
D. E. Kopanoff (1978)
HIV Incidence, Retention, and Changes of High-Risk Behaviors Among Rural Injection Drug Users in Guangxi, China
L. Wei (2006)
Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies
M. Egger (2002)
Fatal Mycobacterium tuberculosis bloodstream infections in febrile hospitalized adults in Dar es Salaam, Tanzania.
L. Archibald (1998)
Case finding for HIV-positive youth: a special type of hidden population.
D. Bell (2003)
Recent studies in the epidemiology of tuberculosis, based on the risk of being infected with tubercle bacilli.
I. Sutherland (1976)
Pharmacokinetics of Adjusted-Dose Lopinavir-Ritonavir Combined with Rifampin in Healthy Volunteers
C. L. la Porte (2004)
Evaluation of World Health Organization criteria for antiretroviral treatment failure in resource-limited settings
P Mee (2006)
Tuberculosis and the HIV epidemic: increasing annual risk of tuberculous infection in Kenya, 1986-1996.
J. Odhiambo (1999)
Tanzanian National tuberculin survey, 4th round results of interim analysis of 12 regions
SM Egwaga (2003)
A clinical and pathological comparison of the WHO and CDC case definitions for AIDS in Kinshasa, Zaïre: is passive surveillance valid?
A. Nelson (1993)
Isoniazid hepatotoxicity among drug users: the role of hepatitis C.
A. Fernández-Villar (2003)
The International Union Against Tuberculosis and Lung Disease model National Tuberculosis Programmes.
D. Enarson (1995)
Scaling Up Antiretroviral Therapy in Resource-Limited Settings: Treatment Guidelines for a Public Health Approach
J. Curran (2005)
Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa
P. Mee (2008)
Global trends in resistance to antituberculosis drugs.
M. Espinal (2001)
Short-term CD4 cell response after highly active antiretroviral therapy initiated at different times from seroconversion in 1,500 seroconverters.
A. Babiker (2003)
Cotrimoxazole prophylaxis reduces mortality in human immunodeficiency virus-positive tuberculosis patients in Karonga District, Malawi.
F. Mwaungulu (2004)
HIV infection and the duration and control of prevalent tuberculosis disease in Harare, Zimbabwe
Elizabeth L. Corbett (2005)
Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort
D. Konopnicki (2005)
Stable incidence rates of tuberculosis (TB) among human immunodeficiency virus (HIV)-negative South African gold miners during a decade of epidemic HIV-associated TB.
E. Corbett (2003)
A randomized, controlled trial of interventions to improve adherence to isoniazid therapy to prevent tuberculosis in injection drug users.
R. Chaisson (2001)
Trust and the Acceptance of and Adherence to Antiretroviral Therapy
F. Altice (2001)
Voluntary counselling, HIV testing and adjunctive cotrimoxazole reduces mortality in tuberculosis patients in Thyolo, Malawi
R. Zachariah (2003)
Value of chest radiography in a tuberculosis prevention programme for HIV-infected people, Botswana
B. Mosimaneotsile (2003)
Pharmacokinetic interaction between rifampin and the combination of indinavir and low-dose ritonavir in HIV-infected patients.
U. Justesen (2004)
Paradoxical reactions of tuberculosis in patients with the acquired immunodeficiency syndrome who are treated with highly active antiretroviral therapy.
E. Navas (2002)
Impact of combination antiretroviral therapy on the risk of tuberculosis among persons with HIV infection
E. Girardi (2000)
Adherence to HAART: A Systematic Review of Developed and Developing Nation Patient-Reported Barriers and Facilitators
E. Mills (2006)
Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis
Marie‐Louise Newell (2004)
Individual, household and community factors associated with HIV test refusal in rural Malawi
K. Kranzer (2008)
Prevalence of tuberculosis in TB suspects with short duration of cough.
H. Banda (1998)
Rate of comorbidities not related to HIV infection or AIDS among HIV-infected patients, by CD4 cell count and HAART use status.
R. Moore (2008)
Natural history and spectrum of disease in adults with HIV/AIDS in Africa.
A. Grant (1997)
Home collection for frequent HIV testing: acceptability of oral fluids, dried blood spots and telephone results
F. Spielberg (2000)
Manage - ment of persons exposed to multidrug - resistant tuberculosis
R Ridzon (1992)
36 World Health Organisation, UNAIDS. Preventive therapy against tuberculosis in people living with HIV
Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent.
J. Keane (2001)
Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study.
S. Emery (2008)
Autopsy Study of HIV‐1‐Positive and HIV‐1‐Negative Adult Medical Patients in Nairobi, Kenya
F. Rana (2000)
Effects of human immunodeficiency virus infection on recurrence of tuberculosis after rifampin-based treatment: an analytical review.
E. Korenromp (2003)
Shadow on the continent: public health and HIV/AIDS in Africa in the 21st century
K. M. Cock (2002)
A clinical and pathological comparison of the WHO and CDC case definitions for AIDS in Kinshasa, Zaire: is passive surveillance valid? AIDS
AM Nelson (1993)
Joint TB and HIV interventions saved the lives of more than 400 000 people in 2011 alone (eight times
Population based screening for active tuberculosis in a community with endemic TB. 33rd World Conference on Lung Health
Gj Churchyard (2002)
Global Burden of Tuberculosis: Estimated Incidence, Prevalence, and Mortality by Country
C. Dye (1999)
Isoniazid prophylaxis in Alaskan Boarding schools. A comparison of two doses.
G. Comstock (1969)
Prevention of Mother-to-Child Transmission of HIV-1 Through Breast-Feeding by Treating Infants Prophylactically With Lamivudine in Dar es Salaam, Tanzania: The Mitra Study
C. Kilewo (2008)
Changing mortality rates and causes of death for HIV‐infected individuals living in Southern Alberta, Canada from 1984 to 2003
H. Krentz (2005)
Rifampin preventive therapy for tuberculosis infection: experience with 157 adolescents.
M. Villarino (1997)
Population based screening for active tuberculosis in a community with endemic TB
GJ Churchyard (2002)
Aetiology, outcome, and risk factors for mortality among adults with acute pneumonia in Kenya
J.A.G. Scott (2000)
Chronic cough in primary health care attendees, Harare, Zimbabwe: diagnosis and impact of human immunodeficiency virus
SS Munyati (2005)
Removing Barriers to Knowing HIV Status: Same-Day Mobile HIV Testing in Zimbabwe
S. Morin (2006)
Use-Effectiveness of the Female Versus Male Condom in Preventing Sexually Transmitted Disease in Women
P. French (2003)
Comparing costs and effectiveness of different starting points for highly active antiretroviral therapy in HIV-positive patients
M. Merito (2005)
Antituberculosis drug resistance and anonymous HIV surveillance in tuberculosis patients in Botswana, 2002
L. Nelson (2005)
Molecular and Conventional Epidemiology ofMycobacterium tuberculosis in Botswana: a Population-Based Prospective Study of 301 Pulmonary Tuberculosis Patients
S. Lockman (2001)
96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures
M. Johnson (2006)
Acetylation rates and monthly liver function tests during one year of isoniazid preventive therapy.
J. R. Mitchell (1975)
HIV infection and the duration and control of prevalent tuberculosis disease in Harare
El Corbett (2005)
Tuberculosis preventive therapy in HIV-infected individuals.
Monitoring the response to antiretroviral therapy in resource-poor settings: the Malawi model.
A. Harries (2004)
Tuberculosis and HIV infection in sub-Saharan Africa.
K. D. De Cock (1992)
Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis.
E. Nuermberger (2004)
Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. International Union Against Tuberculosis Committee on Prophylaxis.
Tuberculosis and the HIV epidemic: increasing annual risk of infection in Kenya, 1986–1996
JA Odhiambo (1999)
Efficacy of secondary isoniazid preventive therapy among HIV-infected Southern Africans: time to change policy?
G. Churchyard (2003)
Radiologic manifestations of pulmonary tuberculosis in HIV-1 and HIV-2-infected patients in Abidjan, Côte d'Ivoire.
L. Abouya (1995)
Short-Course Rifampin and Pyrazinamide Compared with Isoniazid for Latent Tuberculosis Infection: A Multicenter Clinical Trial
R. Jasmer (2002)
Block appointments in an overloaded South African health centre: quantitative and qualitative evaluation.
H. Mahomed (1998)
Clinical efficacy of early initiation of HAART in patients with asymptomatic HIV infection and CD4 cell count > 350 × 106/l
M. Opravil (2002)
This paper is referenced by
Benchmarking to Assess Potential Under-Diagnosis of Smear-Negative and Extrapulmonary Tuberculosis. A Case Study from Mozambique
M. Brouwer (2013)
Pulmonary tuberculosis: virulence of Mycobacterium africanum and relevance in HIV co-infection.
C. Meyer (2008)
Feasibility of routine HIV testing among TB patients through a voluntary counselling and testing centre.
B. Thomas (2007)
Future of HIV/AIDS Care in Low- and Middle- Income Countries
C. Hoffmann (2008)
Use of a codon alteration strategy in a novel approach to cloning the Mycobacterium tuberculosis diaminopimelic acid epimerase.
V. Usha (2006)
Bovine Tuberculosis in Ghana
D. Yeboah-Manu (2019)
Tuberculosis serosurveillance and management practices of captive African elephants (Loxodonta africana) in the Kavango-Zambezi Transfrontier Conservation Area.
L. E. Rosen (2018)
Global epidemiology of venous thromboembolism in people with active tuberculosis: a systematic review and meta-analysis
C. Danwang (2020)
Perceptions of HIV, AIDS and tuberculosis among patients on antiretroviral therapy in Bulawayo, Zimbabwe: implications for the provision of HIV and TB care services
A. Roedlach (2012)
Pulmonary Tuberculosis as a comorbid condtion in HIV positive adults and its effects on Neuro-cognitive function in Zambia
J. Chinyama (2014)
Tuberculosis: the elephant in the AIDS clinic?
B. Marston (2006)
CD8 T-cell-mediated protection against liver-stage malaria: lessons from a mouse model
Natalija Van Braeckel-Budimir (2014)
Prospects for tuberculosis elimination.
C. Dye (2013)
Blood cultures for the diagnosis of multidrug-resistant and extensively drug-resistant tuberculosis among HIV-infected patients from rural South Africa: a cross-sectional study
S. Heysell (2010)
PEPFAR public health evaluation -- care and support. Phase 2 Uganda.
Tuberculosis, incarceration, and HIV at a crossroads in Guyana.
Curtis La Fleur (2012)
Advances in tuberculosis
A. Aseffa (2013)
Optimal versus suboptimal treatment for HIV-infected pregnant women and HIV-exposed infants in clinical research studies.
A. J. Ammann (2009)
Integration of tuberculosis and HIV services in sub-Saharan Africa: lessons learned.
A. Howard (2010)
Clinical and pathological characteristics of the Uganda genotype of Mycobacterium tuberculosis
D. Wamala (2016)
Impact of HIV on novel therapies for tuberculosis control
M. S. Sánchez (2008)
Tuberculosis and Atypical Mycobacterial Infections
J. L. Johnson (2006)
Tuberculosis in pregnancy
CN Mnyani (2011)
Cavernas pulmonares gigantes cicatrizadas, no colapsadas que simulan bulas de enfisema
Edelberto Fuentes-Valdés (2015)
The Presence of Tuberculosis at the Initiation of Antiretroviral Therapy Predicts Retention in Care: A Retrospective Review of Patients on ART in Nigeria
Joseph E Enegela (2015)
Loss to follow up from isoniazid preventive therapy among adults attending HIV voluntary counseling and testing sites in Uganda.
P. M. Namuwenge (2012)
[Change in the survival of Cuban AIDS patients with tuberculosis in the Highly Active Antiretroviral Therapy (HAART) era].
A. Reyes-Corcho (2008)
Tuberculosis among HIV-positive patients at Butajira Hospital , South-Central Ethiopia
Seada Mohammed (2015)
The impact of alcohol consumption on African people in 2012: an analysis of burden of disease
Carina Ferreira-Borges (2016)
Tuberculosis—a World Health Organization Perspective
M. Espinal (2011)
Permeation of PLGA nanoparticles across different in vitro models.
L. Nkabinde (2012)
Mathematical modelling of the epidemiology of tuberculosis.
P. White (2010)See more